Table 2.
Virus loads in mouse brain and lung in Study 3 six days post-challenge.
| Vaccine construct (VN) |
No. mice in challenge |
Dose (μg) | Percent survival |
No. randomly pre-selected mice |
Brain | Lung | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||||
| Average titer | SD | Undetectable |
Average titer | SD | Undetectable | |||||||
| Proportion | % | Proportion | % | |||||||||
| STF2.HA1-2 | 15 | 10 | 93 | 5 | 0.00E0 | 0.00E0 | 5/5 | 100 | 3.00E4 | 6.71E4 | 4/5 | 80 |
| STF2.HA1-2 | 15 | 3 | 87 | 5 | 0.00E0 | 0.00E0 | 5/5 | 100 | 2.00E4 | 4.47E4 | 4/5 | 80 |
| STF2.HA1-2 | 15 | 1 | 80 | 5 | 0.00E0 | 0.00E0 | 5/5 | 100 | 2.20E5 | 4.38E5 | 3/5 | 60 |
| Placebo | 30 | 0 | 0 | 5 | 8.10E4 | 6.50E0 | 0/5 | 0 | 6.43E7 | 6.43E7 | 0/5 | 0 |
In Study 3, dose of 1, 3, and 10 μg of STF2.HA1-2 (VN) were delivered at 42, 28 and 14 days pre-challenge. Organs were collected from randomly pre-selected animals (N=5) on day 6 post-challenge and evaluated for levels of infectious virus in brain and lung. The group averages with standard deviation are presented.